125 results
F-3ASR
SNY
Sanofi
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
, partnership or other entity classified as a partnership for U.S. federal income tax purposes (or investors thereof), a person liable for to the alternative
F-3ASR
EX-25.1
SNY
Sanofi
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
MW53
M.5.
6. Criticized and classified items:
a. Special mention
K663
M.6.a.
b. Substandard
K664
M.6.b.
c. Doubtful
K665
M.6.c.
d. Loss
K666
M.6.d.
7
6-K
EX-99.2
SNY
Sanofi
28 Jul 23
Condensed Half-year Consolidated Financial Statements
7:00am
liabilities (in an amount of €23 million). That liability is classified as a financial liability at amortized cost under IFRS 9. Other than royalty
6-K
EX-99.1
SNY
Sanofi
28 Jul 23
Condensed Half-year Consolidated Financial Statements
7:00am
(Fair Value Measurement) and IFRS 7 (Financial Instruments: Disclosures), fair value measurements must be classified using a hierarchy based … of 2023, including €94 million classified within the line item Other revenues corresponding to doses for which there was no longer any delivery
11-K
SNY
Sanofi
28 Jun 23
Annual report of employee stock purchases
2:32pm
. They are classified within Level 1 of the valuation hierarchy.
Sanofi Puerto Rico Group Savings Plan
Notes to the Financial Statements
December 31, 2022 and 2021 … expedient to measure fair value have not been classified in the fair value hierarchy in accordance with Accounting Standards Codification (“ASC
11-K
4ntxmozafbqh1ber0j
28 Jun 23
Annual report of employee stock purchases
2:31pm
6-K
EX-99.1
qqh2tqe smfyw
28 Jul 22
Condensed Half-year Consolidated Financial Statements
6:17am
11-K
0xbefk0ijhw88ksttl1
29 Jun 22
Annual report of employee stock purchases
11:48am
11-K
3mozdova6m4
29 Jun 22
Annual report of employee stock purchases
11:46am
6-K
EX-99.1
7h7anfo
4 Apr 22
Distribution of Shares of Euroapi
11:21am
SC TO-T
EX-99
lf1ex0p3pwy6 i37b8
16 Aug 21
Third party tender offer statement
8:09am
F-3ASR
vxa 9fdu78rw
30 Jul 21
Automatic shelf registration (foreign)
4:52pm
6-K
EX-99.1
6b6phq4
29 Jul 21
Current report (foreign)
10:48am
11-K
bfhd5cec5ls90
29 Jun 21
Annual report of employee stock purchases
12:30pm
11-K
fx3uef
29 Jun 21
Annual report of employee stock purchases
12:01pm
6-K
EX-99.2
m4sy4y 3cqpz4nc
21 May 21
Sanofi to showcase data from its transformative oncology pipeline at 2021 ASCO Meeting
4:16pm
6-K
EX-99.1
lt6r6tjoi
19 Mar 21
Phase 3 trial of Libtayo® (cemiplimab) monotherapy in advanced cervical cancer stopped early for positive result on overall survival
3:49pm
SC TO-T
EX-99
d3oo29kwjzh 7o
28 Aug 20
Third party tender offer statement
6:24am